[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Brown University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":663},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,52,86,107,138,162,188,215,242,261,288,301,325,351,373,392,417,439,462,487,510,562,591,611,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053402","technology-assisted-methods-to-advance-suicide-prevention-among-youth-in-colombia-100053402",false,"NCT06651554","Technology-assisted Methods to Advance Suicide Prevention Among Youth in Colombia","Harnessing Technology-assisted Methods to Advance Suicide Prevention Among Youth in Colombian School Settings","Inclusion Criteria for youth:\n\n* aged 14-19\n* attending a secondary school in Bogota\n* willing to try the digital platform\n\nExclusion Criteria for youth:\n\n* not meeting inclusion criteria",true,"ALL","14 Years","19 Years",{"count":22,"type":23},228,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will investigate a multi-level approach that applies technology-assisted methods to reduce suicidal thoughts and behaviors (SIB) and promote mental health among Colombian youth: (a) digital platform for youth; (b) digital platform for teachers; and (c) hybrid mental health training diploma program for teachers. This approach will evaluate an open-access digital platform for suicide prevention among Colombian youth. Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. The digital platform's teacher interface will incorporate psychoeducation, brief suicide-risk screening and decision support tools to enhance teacher capacity to assess risk for suicide and refer youth to the appropriate level of services.\n\nStudy investigators will conduct a hybrid-type 1 implementation-effectiveness stepped wedge pilot trial design to evaluate the digital platform and hybrid mental health teacher training program implemented within secondary schools in Bogota, Colombia. Study aims are to:\n\nAim 1. An initial needs assessment will be conducted with key stakeholders (youth, teachers, caregivers, school administrators) to identify barriers and facilitators to successful implementation of the multi-level approach. User-centered design methods will be used to refine the digital platform and incorporate end-user feedback into the final prototype.\n\nAim 2. Investigators will evaluate: (a) feasibility, acceptability, and usability of the digital platform across three schools in Colombia; and (b) the preliminary effects of the digital platform in reducing SIB and improving mood (e.g., anxiety\u002Fdepression) among Colombian youth aged 14-19 attending the three schools. Safety planning skills acquisition (youth-level) and linkages to mental health services (service-level) will be assessed as potential mechanisms of change.\n\nAim 3. The study will apply a multi-disciplinary capacity building model to strengthen behavioral health and implementation science research, healthcare delivery capacity, and mental health policy. In partnership with Pontificia Javeriana University, experts in suicide prevention, data science, and implementation science will be engaged to build in-country research capacity at the individual and institutional level.",[29,30,31,32],"Suicidal Ideations","Suicidal Behaviors","Depression, Anxiety","Well-being",[34,35,36,37,38],"suicide prevention","adolescent health","mHealth","Colombia","Implementation Science","RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":43},"2025-05-12",{"date":47,"type":23},"2027-01-31",{"name":49,"class":50},"Brown University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":51},"100054022","phase-1-egfr-targeted-photoimmunotherapy-with-asp-1929-for-locally-advanced-pancreatic-cancer-100054022","NCT07698613","EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","BrUOG 438: EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed pancreatic adenocarcinoma.\n2. Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.\n3. Completed neoadjuvant chemotherapy\n4. Neoadjuvant radiation is allowed\n5. Planned surgical exploration\n6. Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.\n7. Patients with a history of biliary obstruction must have adequate biliary drainage.\n8. Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:\n\n   Platelet Count ≥ 75,000\u002Fmm3. Hemoglobin ≥ 8.0 g\u002FdL \\[NOTE: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g\u002FdL are not eligible\\] Absolute neutrophil count ≥ 1,000\u002Fmm3. \\[Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1\\] Alanine aminotransferase (ALT) ≤ 3×ULN Aspartate aminotransferase (AST) ≤ 3×ULN Total Bilirubin ≤ 1.5×ULN or \\\u003C 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) Creatinine ≤ 3×ULN\n9. Age ≥ 18\n10. ECOG performance status 0-1\n11. For women of pregnancy potential, a negative pregnancy test within 7 days prior to registration.\n12. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with distant metastases.\n2. Patients with medical co-morbidities that make them not candidates for surgical exploration\n3. Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929\n4. Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.\n5. History of significant (Grade ≥ 3) cetuximab infusion reactions\n6. Photosensitizing medications must be discontinued 4 weeks before ASP-1929 PIT treatment, unless medically required.\n7. No uncontrolled intercurrent illness including but not limited to symptomatic CHF, unstable angina, clinically significant severe cardiac arrhythmia, psychiatric illness or social situations that would limit compliance with study requirements.\n8. Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive ASP-1929 and\u002For be exposed to PIT illumination.\n9. Women who are pregnant or nursing.\n10. Patients with concomitant malignancies not expected to cause death within 5 years are eligible.","18 Years",{"count":61,"type":23},30,[63,64],"PHASE1","PHASE2","This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.",[67,68,69],"Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection","Pancreatic Cancer Borderline","Pancreatic Cancer Resectable",[71,72,73,74,75,76,77],"ASP-1929","photoimmunotherapy","EGFR targeting antibody","laser-light activable dye IR700","IRDye 700DX","RM-1929","cetuximab sarotalocan","NOT_YET_RECRUITING","2026-07-07",{"date":42,"type":43},{"date":82,"type":23},"2026-09",{"date":84,"type":23},"2033-09",{"name":49,"class":50},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":51},"100644386","targeting-alcohol-opioid-co-use-among-young-adults-using-a-novel-mhealth-intervention-100644386","NCT07663448","Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention","Inclusion Criteria:\n\n1. Ages 18 to 25 years, inclusive\n2. Self-report interest in reducing their alcohol-opioid co-use - outside a research study, people who do not wish to change their co-use are unlikely to download and use an mHealth app designed to reduce co-use. It is important to recruit participants who most closely resemble the intended users of the eventual mHealth intervention. This is defined as reporting any alcohol-opioid co-use goal (i.e., not selecting \"No goal\" in response to the alcohol-opioid co-use goal question at the screening visit).\n3. Self-report engaging in simultaneous alcohol-opioid co-use (i.e., use of both substances within two hours) ≥ 1 day\u002Fweek on average in the past 28 days (i.e., at least 4 co-use events in the past 28 days). This requirement will ensure that we observe sufficient use episodes where the pharmacological effects of alcohol and opioids overlap to evaluate project aims.\n4. Able to understand written and oral instructions in English, communicate understanding of the consent form, and provide written informed consent.\n5. Complete all assessments required at screening.\n6. Agree to the schedule of visits, verbally acknowledge that he\u002Fshe\u002Fthey will be able to attend each scheduled visit, participate in phone visits and that he\u002Fshe\u002Fthey does not have any already scheduled events or a job that may substantially interfere with study participation.\n7. Own a smartphone with data plan. Almost all participants (98%) in our preliminary work owned a smartphone with data plan.\n8. Currently reside in the United States of America.\n\nExclusion Criteria:\n\n1. Pregnant or nursing\n2. Current suicidality\n3. History of psychosis","25 Years",{"count":61,"type":23},[26],"The goal of this treatment development project is to develop and pilot an adaptive mobile health (mHealth) intervention that targets the co-use of alcohol and opioids in young adults.",[97,98],"Alcohol Drinking","Opioid Use","2026-06-17",{"date":101,"type":43},"2026-06-23",{"date":103,"type":43},"2026-06-08",{"date":105,"type":23},"2027-04-30",{"name":49,"class":50},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":51},"100641183","phase-1-tlr9-immunotherapy-for-peritoneal-carcinomatosis-100641183","NCT07658196","TLR9 Immunotherapy for Peritoneal Carcinomatosis","TLR9 Immunotherapy for Peritoneal Carcinomatosis (TIPC) - Phase 1 Study of the Safety and Efficacy of ACM-CpG Intraperitoneal Injections for Treatment in Patients With Colorectal or Appendiceal Adenocarcinoma Peritoneal Metastases or Malignant Ascites","TIPC","Inclusion Criteria:\n\n* Patients eligible for inclusion in this study must meet all of the following criteria:\n\n  1. Male or female patients age ≥ 18 years of age at the time of informed consent\n  2. Must be able to provide written informed consent, stating an understanding of the procedures and investigational nature of the study treatment, and willingness to comply with study requirements\n  3. Must have documented CRC or appendiceal adenocarcinoma peritoneal carcinomatosis or malignant ascites. Primary tumor may be intact and limited liver and\u002For lung disease is permitted\n  4. Must have evaluable disease by physical examination, serum tumor markers, radiologic assessment, or laparoscopic visual assessment\n  5. Must have a life expectancy of ≥ 12 weeks as estimated by the investigator\n  6. Must have an ECOG status of ≤ 2\n  7. Patients with acceptable laboratory values defined as:\n\n     * Estimated creatinine clearance (calculated using Cockcroft-Gault formula, or measured) ≥ 60 mL\u002Fmin, not dialysis dependent\n     * Total bilirubin ≤ 1.5 mg\u002Fdl, unless elevated bilirubin is clearly related to Gilbert syndrome (and total bilirubin \\\u003C 6.0 mg\u002Fdl)\n     * Alanine aminotransferase (ALT) ≤ 3.5 x upper limit of normal (ULN)\n     * Aspartate aminotransferase (AST) ≤ 3.5 x ULN\n     * Absolute neutrophil count \\> 1.0 x 109\u002FL (must be independent of blood product administration)\n     * Platelet count \\> 100 x 109\u002FL (must be independent of blood product administration)\n     * Hemoglobin ≥ 8 g\u002FdL (must be independent of blood product administration)\n  8. Surgically sterile patients or patients of childbearing potential (CBP) who agree to use highly effective methods of contraception during study dosing and for 6 months after last dose of study drug\n  9. All other relevant medical conditions must be well-managed and stable, in the opinion of the investigator, for at least 28 days prior to administration of study drug\n\nExclusion Criteria:\n\n1. Has received prior TLR9 therapy\n2. Has received chemotherapy, radiotherapy, or biological cancer therapy within 21 days or 5 half-lives (whichever is shorter) of the start of treatment\n3. Has received an investigational agent within 28 days of the start of treatment\n4. Has received a commercial vaccine (flu, COVID, etc.) within 2 weeks of C1D1\n5. Has any unresolved toxicity ≥ Grade 2 from previous anti-cancer therapy, except for stable chronic toxicities (≤ Grade 3) that are not expected to resolve\n6. Has a history of histologically confirmed metastases outside of the peritoneal cavity, liver, or lungs\n7. Has high volume liver or lung metastases, defined as \\> 50% replacement of the liver volume by metastatic disease or \\> 5 lung lesions greater than 1 cm in size\n8. Tumor causing biliary obstruction not amenable to stenting or percutaneous drainage\n9. Ongoing or untreated intra-abdominal infection or bowel obstruction\n10. Has known, clinically active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) (Note: Testing is not required)\n11. Receiving continuous systemic corticosteroid therapy (≥ 10 mg\u002Fday of prednisolone or equivalent)\n12. Clinically significant cardiac disease or impaired cardiac function, including any of the following:\n\n    * A history of newly diagnosed transmural myocardial infarction, cerebral infarction, or pulmonary embolism within 6 months, except those approved by the medical monitor\n    * A history of newly diagnosed deep vein thrombosis (DVT) within 3 months\n    * Left ventricular ejection fraction (LVEF) \\\u003C 50%\n    * QTc \\>480 msec\n13. Active bacterial, viral, or fungal infection: patients with ongoing use of prophylactic antibiotics, antiviral agents, or antifungal agents remain eligible as long as there is no evidence of active infection\n14. Other active malignancy within 2 years excluding cutaneous squamous or basal cell carcinomas\n15. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results\n16. History of hypersensitivity to TLR9 agonists\n17. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)",{"count":116,"type":23},24,[63],"The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are:\n\n• To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy.\n\nParticipants will:\n\n* Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatment cycle.\n* May receive up to 2 additional injections if they have clinically stable or responsive disease.\n* Must visit the clinic on Days 1, 4, 7, 10, 14, 21, and 28 for checkups and tests.\n* Will have a CT scan or MRI performed every 8 weeks for 3 scans and then continue to receive scans every 12 weeks to monitor their disease.",[120,121,122,123],"Malignant Ascites","Colorectal Adenocarcinoma","Peritoneal (Metastatic) Cancer","Appendiceal Adenocarcinoma",[125,126,127,120,128,123,129],"Metastatic disease must be primarily located in the peritoneal cavity","ACM-CpG","TLR9","Peritoneal Carcinomatosis,","CRC","2026-06-16",{"date":132,"type":43},"2026-06-18",{"date":134,"type":23},"2026-07",{"date":136,"type":23},"2030-07",{"name":49,"class":50},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":51},"100594161","generalization-and-specificity-of-visual-learning-during-sleep-100594161","NCT07015840","Generalization and Specificity of Visual Learning During Sleep","Visuallearning","Inclusion Criteria:\n\n* 18 - 30 years old\n* Normal or corrected to normal visual acuity\n\nExclusion Criteria:\n\n* Self-report of visual and eye disorders (cataracts, age-related macular degeneration, diabetic retinopathy, glaucoma)\n* Drug use (psychoactive drugs, neuroleptic medications, prescription medications that might affect cognitive and motor performance)\n* History of sleep disorders (sleep apnea, insomnia)\n* Failure to meet the criteria on the visual acuity test\n* Magnetically or mechanically activated implants (such as cardiac pacemakers)\n* Clips on blood vessels in the brain\n* Use of any type of intrauterine devices\n* Use of dentures\n* Pregnancy","30 Years",{"count":147,"type":23},10,[26],"A growing body of evidence suggests that sleep facilitates and is beneficial to perceptual learning. However, the underlying mechanism of this facilitatory action is largely unknown. One must know what type of processing occurs during sleep to clarify the mechanism of sleep facilitating perceptual learning. For this purpose, investigators will obtain highly localized spatio-temporal information about brain activation during sleep using magnetic resonance imaging (MRI) and polysomnography (PSG) measurement.",[151,152],"Visual Learning","Healthy Volunteers",[154,155],"Sleep","Behavioral",{"date":157,"type":43},"2026-06-10",{"date":159,"type":43},"2025-02-01",{"date":134,"type":23},{"name":49,"class":50},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":17,"sex":169,"minAge":59,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100508541","phase-4-effect-of-iodine-containing-multiple-micronutrient-during-lactation-on-infant-neurodevelopment-100508541","NCT05901766","Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment","Effect of Maternal Supplementation With an Iodine-containing Multiple Micronutrient During Lactation on Infant Iodine Status, Thyroid Function and Neurodevelopment","To be eligible, women will be required to meet the following inclusion criteria:\n\n* Maternal age 18 years or above, singleton pregnancy,\n* data available on Last Menstrual Period (LMP) or early ultrasound,\n* Intention to exclusively feed breastmilk for 4 to 6 months,\n* Intention to stay in the study catchment area for at least 6 months,\n* Willingness to take a daily supplement of MMS for 6 months\n\nExclusion criteria include:\n\n* Severe maternal morbidity (postpartum eclampsia, postpartum hemorrhage),\n* Maternal condition leading to inability for infant to directly\u002Fexclusively breastfeed (maternal mastectomy, or other breast surgery),\n* Breast cancer,\n* Tuberculosis","FEMALE",{"count":171,"type":23},600,[173],"PHASE4","The goal of this clinical trial is to learn about the effects of iodine-containing multiple micronutrient supplements provided to breastfeeding mothers who live in settings with mild iodine deficiency.\n\nThe main questions it aims to answer are:\n\n1. What are the effects of iodine-containing multiple micronutrient supplements provided to breastfeeding mothers on infant development, as measured by electroencephalography\u002Fvisual evoked potentials?\n2. What are the effects of iodine-containing multiple micronutrient supplements on breast milk concentrations of iodine, and infant iodine and thyroid status?\n3. How do iodine and iron interact with each other to affect thyroid function in the mother during lactation?\n\nParticipants will be randomized to receive a daily multiple micronutrient tablet containing iodine (UNIMAPP) for 6 months postpartum, or routine postnatal care per Ethiopia Ministry of Health. Mothers will provide a breast milk sample and blood at 3 and 6 months postpartum. Infants will provide a urine sample and drop of blood, and have a neurodevelopmental assessment at 3 and 6 months.\n\nResearchers will compare the groups that received the iodine-containing micronutrient supplement with the group that received routine care and see if there were any benefits on infant development and iodine and thyroid status in the mother and baby.",[176,177,178,179],"Iodine Deficiency","Nutrition Poor","Development, Infant","Breastfeeding","2026-05-21",{"date":182,"type":43},"2026-05-26",{"date":184,"type":23},"2026-05-01",{"date":186,"type":23},"2028-03-31",{"name":49,"class":50},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":51},"100588949","clinical-research-evaluating-smoking-cessation-with-e-cigarettes-and-nicotine-therapy-100588949","NCT06948058","Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy","CRESCENT","Inclusion Criteria:\n\n* body mass index (BMI) ≥ 30 kg\u002Fm2 (i.e., obese)\n* smoked ≥ 5 cigarettes\u002Fday during the past year\n* 21 or older (due to minimum legal age EC restrictions)\n* exhaled breath carbon monoxide (CO) level \\> 6 ppm at Baseline (BL) (to confirm self-reported smoking)\n* willing to use EC or NRT for 8 weeks\n* access to a Bluetooth-enabled smartphone\u002Ftablet (to permit remote measurement of CO and other outcome variables)\n\nExclusion Criteria:\n\n* received smoking cessation treatment of any kind in the past 30 days (actively quitting smoking),\n* currently using EC or NRT more than 2 days\u002Fweek (this may affect responses to study-supplied products)\n* hospitalized for mental illness in past 30 days\n* heart-related event (e.g., heart attack, severe angina) in past 30 days\n* residing with another person currently enrolled in the study\n* pregnant, nursing, or planning to become pregnant in the next 6 months\n* medical contraindication for study or product use (e.g., allergy to adhesives)\n* taken prescription weight loss medication in the last 30 days","21 Years",{"count":197,"type":23},60,[26],"This project will investigate the effects of alternative nicotine products on smoking, weight gain, and related outcomes.",[201,202],"Smoking Cessation","Obesity and Obesity-related Medical Conditions",[204,205,206],"obesity","electronic cigarettes","harm reduction","2026-05-14",{"date":209,"type":43},"2026-05-18",{"date":211,"type":43},"2025-04-01",{"date":213,"type":23},"2027-08-31",{"name":49,"class":50},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":224,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100633819","from-screening-to-safety-implementing-the-al-steadi-initiative-in-assisted-living-communities-100633819","NCT07531641","From Screening to Safety: Implementing the AL-STEADI Initiative in Assisted Living Communities","AL-STEADI","Inclusion Criteria: This is a pragmatic trial. All residents living in one of the seven participating assisted living communities will be potentially eligible. Residents who screen positive for fall risk will be enrolled.\n\n\\-\n\nExclusion Criteria: Not living in one of seven partnering assisted living centers. Not screening at-risk for falls.\n\n\\-",{"count":223,"type":23},700,[26],"The goal of this trial is to test the real-world efficacy of AL-STEADI, a fall prevention program, in seven assisted living centers. We will randomly assign 700 residents from seven assisted living centers who screen at-risk of falling to either existing fall monitoring protocols or the enhanced AL-STEADI fall prevention program. We will evaluate the effect of AL-STEADI on the rate of falls over 12 months. We will also closely monitor implementation fidelity in these seven assisted living centers.",[227,228,229],"Fall","Fall Injury Prevention","Fall Prevention",[231,232,233],"assisted living","fall prevention","STEADI","2026-04-09",{"date":236,"type":43},"2026-04-15",{"date":238,"type":23},"2027-06",{"date":240,"type":23},"2029-09",{"name":49,"class":50},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":51},"100434190","phase-2-bruog-397-neo-rad-low-neoadjuvant-low-dose-stereotactic-body-radiotherapy-ipilimumab-and-nivolumab-100434190","NCT04933903","BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed NSCLC\n2. Age \\> 18\n3. ECOG Performance Status 0-1.\n4. Pulmonary function capacity capable of tolerating the proposed lung resection. FEV1 at least 2 L. If less than 2 L, the predicted postoperative forced expiratory volume in 1 second (FEV1) must be \\> 0.8 L or be \\> 35% of the predicted value. Postoperative predicted DLCO ≥ 35% is required.\n5. Resectable stage IB-IIIB (T2-3N0, T1-T3N1-2) NSCLC (per the 8th Edition American Joint Committee on Cancer (AJCC) classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable.\n6. N2 nodes must be discrete (ie, not invading surrounding structures). If patients have N2 disease, as suspected by CT or PET, histologic proof of N2 status is recommended.\n7. Patients must be evaluated by a Thoracic Surgeon prior to registration. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality. Absence of major associated comorbidities that increase the surgery risk to an unacceptable level.\n8. No prior history of thoracic radiation.\n9. Adequate Organ and marrow function as defined below\n\n   * leukocytes ≥2,000\u002FmcL,\n   * absolute neutrophil count ≥1,000\u002FmcL,\n   * platelets ≥100,000\u002FmcL,\n   * Hemoglobin \\>8.0 g\u002FdL\n   * Total bilirubin within normal institutional limits\n   * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional upper limit of normal\n   * creatinine within normal institutional limits OR creatinine clearance ≥50 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels above institutional normal.\n10. Patients are capable of giving informed consent and\u002For have an acceptable surrogate capable of giving consent on the subject's behalf.\n11. Nonpregnant and non-nursing. The effect of ipilimumab and nivolumab on the fetus is unknown.\n12. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \\>1 year.\n13. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n14. Women \\\u003C50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n15. Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n16. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n17. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.\n\nExclusion Criteria:\n\n1. Pathologically confirmed NSCLC \\*\n2. Age \\> 18 \\*\n3. ECOG Performance Status 0-1.\n4. Pulmonary function capacity capable of tolerating the proposed lung resection. FEV1 at least 2 L. If less than 2 L, the predicted postoperative forced expiratory volume in 1 second (FEV1) must be \\> 0.8 L or be \\> 35% of the predicted value. Postoperative predicted DLCO ≥ 35% is required.\n5. Resectable stage IB-IIIB (T2-3N0, T1-T3N1-2) NSCLC (per the 8th Edition American Joint Committee on Cancer (AJCC) classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable.\n6. N2 nodes must be discrete (ie, not invading surrounding structures). If patients have N2 disease, as suspected by CT or PET, histologic proof of N2 status is recommended.\n7. Patients must be evaluated by a Thoracic Surgeon prior to registration. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality. Absence of major associated comorbidities that increase the surgery risk to an unacceptable level. \\*\n8. No prior history of thoracic radiation.\n9. Adequate Organ and marrow function as defined below\n\n   * leukocytes ≥2,000\u002FmcL,\n   * absolute neutrophil count ≥1,000\u002FmcL,\n   * platelets ≥100,000\u002FmcL,\n   * Hemoglobin \\>8.0 g\u002FdL\n   * Total bilirubin within normal institutional limits\n   * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional upper limit of normal\n   * creatinine within normal institutional limits OR creatinine clearance ≥50 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels above institutional normal.\n10. Patients are capable of giving informed consent and\u002For have an acceptable surrogate capable of giving consent on the subject's behalf.\n11. Nonpregnant and non-nursing. The effect of ipilimumab and nivolumab on the fetus is unknown.\n12. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \\>1 year.\n13. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n14. Women \\\u003C50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n15. Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n16. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n17. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.",{"count":7,"type":23},[64],"This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery will be evaluable for the primary endpoint. The primary efficacy outcome measurement will be pathologic response (including Major Pathologic Response (MPR), and Complete Pathologic Response (CPR)). Secondary outcome measures include safety, and exploratory biomarkers of immune response in pre- and post-operative blood and tissue. A two-stage design will stop the study if fewer than 3 of the first 9 evaluable patients do not achieve MPR. An early stopping rule for safety will stop the study if more than 12 patients are enrolled to find the first 9 evaluable patients.",[253],"Non Small Cell Lung Cancer","2026-03-30",{"date":256,"type":43},"2026-03-31",{"date":258,"type":43},"2021-10-05",{"date":82,"type":23},{"name":49,"class":50},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":24,"phases":270,"briefSummary":271,"conditions":272,"keywords":277,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":285,"leadSponsor":287,"locationsCount":51},"100631606","phase-2-tpg-tafasitamab-polatuzumab-vedotin-and-glofitamab-as-first-line-therapy-for-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-100631606","NCT07502872","TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","TPG","Inclusion Criteria:\n\n1. Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures.\n2. Age ≥18 years.\n3. Histologically confirmed diagnosis of DLBCL, or HGBL, according to 5th edition WHO classification. Eligible WHO entities include:\n\n   * Diffuse large B-cell lymphoma, not otherwise specified (NOS)\n   * T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n   * DLBCL\u002FHGBL with MYC and BCL2 rearrangements\n   * Large B-cell lymphoma with IRF4 rearrangement\n   * HGBL with 11q aberration\n   * EBV-positive diffuse large B-cell lymphoma\n   * DLBCL associated with chronic inflammation\n   * Primary large B-cell lymphoma of immune-privileged sites\n   * Primary cutaneous DLBCL, leg type\n   * Intravascular large B-cell lymphoma\n   * Primary mediastinal large B-cell lymphoma\n   * HGBL, NOS\n   * Grade 3B follicular lymphoma.\n4. FDG-avid disease by PET-CT Lugano criteria.\n5. No prior systemic therapy for B-cell lymphoma, except for:\n\n   * corticosteroids;\n   * a single cycle of chemotherapy administered prior to enrollment (to facilitate enrolling patients who require emergent initiation of therapy for rapidly progressive or symptomatic lymphoma);\n   * prior local radiation therapy;\n   * prior treatment for indolent lymphoma.\n6. Performance status ECOG 0, 1, or 2.\n7. Ability to receive one of the standard chemotherapy regimens for DLBCL\u002FHGBL including attenuated versions, where clinically appropriate\n8. Required initial laboratory values: (unless due to underlying lymphoma):\n\n   * absolute neutrophil count ≥1.0 x 109\u002FL,\n   * platelet count ≥75 x 109\u002FL.\n   * creatinine ≤ 1.5 mg\u002FdL or glomerular filtration rate (GFR) ≥40 mL\u002Fmin\u002F1.73m2 using the Mayo Quadratic Formula\n   * total bilirubin ≤ 1.5 × institution upper limit of normal (ULN) unless attributable to Gilbert's disease\n   * AST and ALT ≤ 3 × institution ULN.\n   * Negative antigen or PCR test for SARS-CoV-2.\n9. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) and refrain from donating eggs or sperm throughout the treatment and for 3 months after the last dose of trial therapy.\n\nExclusion Criteria:\n\n1. Pregnancy, breast-feeding, or prisoner status.\n2. Central nervous system involvement by the lymphoma.\n3. Prior solid organ transplantation or allogeneic stem cell transplantation.\n4. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.\n5. Known NYHA class 3\u002F4 congestive heart failure, left ventricular ejection fraction (LVEF) \\\u003C30%, or active ischemic heart disease.\n6. Chronic obstructive pulmonary disease (COPD) requiring continuous oral corticosteroids or chronic oxygen.\n7. Grade \\>1 peripheral neuropathy.\n8. Use of systemic immunosuppressive medications (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 2 weeks prior to first dose of study treatment (except as allowed in the inclusion criteria for the management of lymphoma).\n9. Any of the following conditions:\n\n   * active bacterial infection requiring antibiotics\n   * chronic active Epstein Barr virus (CAEBV) infection\n   * history of hemophagocytic lymphohistiocytosis (HLH)\n   * history of Stevens-Johnson syndrome or toxic epidermal necrolysis\n   * progressive multifocal leukoencephalopathy (PML)\n   * known active EBV or CMV viremia\n   * autoimmune disease requiring systemic immunosuppressive therapy\n   * active myasthenia gravis, myositis, autoimmune hepatitis, idiopathic pulmonary fibrosis, systemic lupus erythematosus, inflammatory bowel disease, granulomatosis with polyangiitis, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n   * active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with a positive total\u002FIgG HBV core antibody (HBcAb) are eligible if (1) HBV DNA is documented at screening, (2) they agree to take entecavir or tenofovir, and (3) they agree to undergo periodic DNA testing. Patients with a positive HCV antibody are eligible if a negative polymerase chain reaction (PCR) for HCV is documented.\n   * HIV infection with a detectable viral load or a CD4 count \\\u003C200 cells\u002Fmm3. Patients (1) with an undetectable viral load and CD4 count \\>200 cells\u002Fmm3 within 6 months prior to enrollment, and (2) on antiretroviral therapy are eligible.\n10. Administration of a live, attenuated vaccine within 4 weeks before first treatment or anticipation that such a live, attenuated vaccine will be required during the study.\n11. History of other malignancy that could affect compliance with the protocol or interpretation of the primary endpoint in the judgement of the investigator.\n12. Any major surgery within 4 weeks before the first dose of treatment.\n13. Evidence of other significant or uncontrolled medical or psychiatric conditions that could affect compliance with the protocol, in the judgement of the investigator.",{"count":61,"type":23},[64],"This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).",[273,274,275,276],"Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Lymphoma","Lymphoma, B-Cell",[278,279,280,281],"glofitamab","polatuzumab vedotin","tafasitamab","immunotherapy","2026-03-25",{"date":256,"type":43},{"date":184,"type":23},{"date":286,"type":23},"2029-12-01",{"name":49,"class":50},{"id":289,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":290,"targetDuration":4,"studyType":24,"phases":291,"briefSummary":27,"conditions":292,"keywords":293,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":51},"100566159",{"count":22,"type":23},[26],[29,30,31,32],[34,35,36,37,38],"2026-03-19",{"date":296,"type":43},"2026-03-23",{"date":45,"type":43},{"date":299,"type":23},"2028-05-31",{"name":49,"class":50},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":51},"100372932","phase-2-alpha-1-blockade-for-alcohol-use-disorder-aud-100372932","NCT04135846","Alpha-1 Blockade for Alcohol Use Disorder (AUD)","A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD","DOXY","Inclusion Criteria:\n\n* Male or female, 18 years of age\n* Meet the DSM-5 criteria for AUD\n* Desire to reduce or quit alcohol drinking\n* Breath alcohol (BrAC) = 0.00 at each visit\n* In good health as confirmed by medical history, physical examination and lab tests\n* Willing to adhere to the study procedures\n* Understand informed consent and questionnaires in English at an 8th grade level\n\nExclusion Criteria:\n\n* Women who are breastfeeding or \u002Fpositive urine test for pregnancy\n* CrCl\\\u003C60mL\u002Fmin\n* Suicide attempt in the last three months\n* Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline\n* Current use of medication that may interact with doxazosin and\u002For yohimbine\n* History of allergy to any alpha receptor blockers\n* Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8\n* Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening\n* Treatment with any alpha-blocker\n* Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG.\n* Baseline hypotension defined as BP reading lower than 90\u002F60 mmHg\n* Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication",{"count":310,"type":23},184,[64],"The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.",[314],"Alcohol Use Disorder (AUD)",[316],"Alcohol use disorder, stress","2026-03-18",{"date":319,"type":43},"2026-03-20",{"date":321,"type":43},"2019-12-19",{"date":323,"type":23},"2026-08-31",{"name":49,"class":50},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":51},"100602062","phase-2-probenecid-administration-for-alcohol-craving-and-consumption-100602062","NCT07118618","Probenecid Administration for Alcohol Craving and Consumption","Probenecid, Pannexin 1 Channels for Alcohol Use Disorder","PROB2","Inclusion Criteria:\n\n* • Male or female, ≥18 years.\n\n  * women \\>7 drinks\u002Fweek; men \\>14 drinks\u002Fweek.\n  * meet moderate to severe AUD score for DSM-5 criteria.\n  * Breath Alcohol Content (BrAC)=0.00 at each visit.\n  * in good health as confirmed by medical history, physical examination and lab tests.\n  * willing to adhere to the study procedures.\n  * understand informed consent and questionnaires in English at an 8th grade level.\n\nExclusion Criteria:\n\n* • Women who are breastfeeding or positive urine test for pregnancy.\n\n  * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \\>150% of the upper normal limit, ALT\u002FAST \\>300% the UNL, creatinine clearance ≤60 dl\u002Fmin\n  * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses\n  * medications that reduce alcohol consumption (naltrexone, disulfiram).\n  * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).\n  * history of suicide attempts in the last three years.\n  * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.\n  * current use of medications that may interact with probenecid.\n  * history of hypersensitivity to sulfa drugs.",{"count":334,"type":23},120,[64],"This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g \u002Fday) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.",[314,338,339],"Alcohol Consumption","Craving",[341,342,339,343],"AUD","Probenecid","Alcohol","2026-03-14",{"date":346,"type":43},"2026-03-17",{"date":344,"type":43},{"date":349,"type":23},"2030-12-31",{"name":49,"class":50},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":92,"enrollmentInfo":358,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":51},"100623577","using-novel-behavioral-economic-measures-to-characterize-dual-marijuana-and-tobacco-use-in-young-adults-100623577","NCT07398443","Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults","MATEY","Inclusion Criteria:\n\n1. Males\u002Ffemales who are 18 to 25 years of age\n2. Young adults who currently smoke commercial tobacco cigarettes (≥1x weekly in the past 30 days and for the past six months)\n3. Young adults who currently smoke marijuana (≥4 times in past 30 days and at least weekly on average for the last six months)\n4. Participants must report purchasing their own tobacco and marijuana at least once in the past 6 months\n5. Participants must speak, comprehend, and read English.\n\nExclusion Criteria:\n\n1. Intention to quit marijuana or tobacco use in the next 30 days\n2. Self-reported illicit drug or heavy episodic alcohol use on \\>20 days in the past month (excluding marijuana)\n3. Individuals who are pregnant or breastfeeding\n4. Positive saliva test for recent THC use\n5. Breath alcohol level above 0 at any session.\n6. Participants who exclusively roll their own tobacco cigarettes",{"count":334,"type":23},[26],"The multi session experimental study aims to determine dual use patterns of marijuana and tobacco by assessing the impact of price and availability of marijuana and tobacco using a cross price elasticity of demand task. The study will recruit 120 non-treatment seeking emerging young adults (18-25 years) who smoke marijuana and tobacco.",[362,363,364],"Behavioral Economics","Cannabis Smoking","Tobacco Smoking","2026-03-02",{"date":367,"type":43},"2026-03-04",{"date":369,"type":43},"2026-02-17",{"date":371,"type":23},"2028-11-30",{"name":49,"class":50},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":51},"100626948","the-dynamics-of-representational-change-underlying-recall-100626948","NCT07442266","The Dynamics of Representational Change Underlying Recall","Exclusion Criteria:\n\n* Under the age of 18 or over the age of 40\n* Does not live in the United States or is not a native speaker of English\n* Diagnosis of a neurological disorders, a history of head trauma, or diagnosis of psychiatric disorder\n* Imperfect and uncorrected visual acuity, color blindness, or imperfect hearing\n* Magnetically or mechanically activated implants or other untested metal implants\n* Claustrophobia","40 Years",{"count":61,"type":23},[26],"The goal of this clinical trial is to examine how repeated memory retrieval changes visual representations in the brain in healthy adult participants. Specifically, the study aims to determine whether repeated recall strengthens or transforms neural representations in visual cortex compared to a time-matched control condition. The main questions it aims to answer are: 1) Does repeated retrieval produce cumulative changes in visual cortical representations compared to a control condition matched for elapsed time? 2) Do these representational changes differ for simple spatial stimuli and complex natural images?\n\nResearchers will compare neural activity patterns during repeated retrieval to those during a control retrieval condition to determine whether repeated recall leads to systematic changes in representational structure beyond those attributable to the passage of time. Participants will: 1) complete two fMRI sessions. 2) Undergo a localizer session including anatomical imaging, population receptive field (pRF) mapping, and a visual category localizer task. 3) Study cue-stimulus pairs consisting of either simple spatial patterns or natural images. 4) Recall previously studied stimuli multiple times during repeated and control retrieval conditions while undergoing fMRI scanning. Brain activity patterns during study and recall will be compared to assess how repeated retrieval influences the structure and tuning of visual representations.",[384],"Episodic Memory","2026-02-27",{"date":365,"type":43},{"date":388,"type":43},"2026-02-03",{"date":390,"type":23},"2026-08",{"name":49,"class":50},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":398,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":24,"phases":401,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":51},"100592794","phase-3-head-and-neck-cancer-study-project-in-the-geriatric-population-100592794","NCT06998069","Head and Neck Cancer Study Project in the Geriatric Population","Inclusion Criteria:\n\n* Patients must have the following\n* Pathology confirmed squamous cell carcinoma of the head and neck (unknown primary is excluded).\n* Confirmed stage of disease between IB and IVA, based on imaging studies.\n* CGA score of 3-5\n* Evaluation by medical oncology and radiation oncology.\n* Patients in the experimental group must be eligible for systemic treatment with chemoimmunotherapy followed by radiation treatment as determined by the geriatric oncology team.\n* Age ≥ 65 years.\n* ECOG performance status ≤ 2\n* Adequate organ and marrow function as defined below:\n\nAbsolute neutrophil count ≥1.0 x 109\u002FL Platelets \\>100,000\u002Fmm3 Total bilirubin \\\u003C1.5 x ULN Aspartate aminotransferase (ast\u002Fsgot) \\\u003C3 x ULN Alanine aminotransferase (alt\u002Fsgpt) \\\u003C3 x ULN Creatinine clearance ≥ 40 mL\u002Fmin as determined by Cockcroft Gault (using actual body weight) or \\\u003C1.5 x Upper limit of normal\n\nMales:\n\nCLcr (mL\u002Fmin) = \"\\[140 - age (years)\\] × weight (kg)\" \u002F\"72 × serum creatinine (mg\u002FdL)\"\n\nFemales:\n\n(CLcr (mL\u002Fmin) = \"\\[140 - age (years)\\] × weight (kg)\" \u002F\"72 × serum creatinine (mg\u002FdL)\" × 0.85\n\n* Patients receiving pembrolizumab must meet standard institutional criteria for immunotherapy including no history of severe autoimmune disease.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with metastases, including treated brain metastases, are not eligible for enrollment.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have previously received systemic chemoimmunotherapy for H\u002FN cancer.\n* Patients with uncontrolled intercurrent illness.","65 Years",{"count":400,"type":23},20,[402],"PHASE3","This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as frail, with a CGA score of 3-5, will then be treated with a novel reduced intensity regimen. The regimen will be tailored based on the programmed cell death ligand 1 combined positive score (PD-L1 CPS) and will involve 4 cycles of systemic chemotherapy and\u002For immunotherapy followed by radiation treatment.",[405],"Head and Neck Neoplasms",[407,408],"Squamous cell carcinoma of the head and neck","Geriatric population","2025-12-28",{"date":411,"type":43},"2025-12-30",{"date":413,"type":43},"2025-08-27",{"date":415,"type":23},"2027-06-01",{"name":49,"class":50},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":24,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":438},"100423334","phase-2-mosunetuzumab-with-lenalidomide-augmentation-as-first-line-therapy-for-follicular-and-marginal-zone-lymphoma-100423334","NCT04792502","Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma","BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma","Inclusion Criteria:\n\n1. Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures.\n2. Age ≥18 years at the time of signing informed consent. Because no dosing or adverse event data are currently available on the use of mosunetuzumab in patients \\\u003C18 years of age, they are excluded from this study.\n3. Histologically confirmed diagnosis of:\n\n   * follicular lymphoma (grade 1, 2, 3a, or not otherwise specified) or\n   * marginal zone lymphoma (nodal, extranodal, or splenic), according to 2016 WHO classification and confirmed to express the CD20 antigen by immunohistochemistry or flow cytometry. Patients in whom definitive pathologic subtype of FL\u002FMZL is undetermined due to limited biopsy material can be enrolled if in the investigator's opinion integrated clinicopathologic data are consistent with the eligible diagnosis.\n4. Agreement to provide, if available, lymphoma tissue for correlative analyses.\n5. At least one bi-dimensionally measurable nodal lesion, defined as \\>1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as \\>1.0 cm in its longest diameter; with the exception of splenic MZL, which must be evaluable using the International SMZL Group criteria.\n6. No prior systemic therapy for B-cell lymphoma, except for palliative corticosteroids; prior local therapy (surgery, radiation therapy, or antibiotics) is allowed.\n7. Indication to start systemic therapy for lymphoma:\n\n   * Patients with FL must meet one of the GELF criteria:\n\n     * any mass ≥7 cm (except spleen);\n     * at least 3 nodes \\>3 cm in diameter;\n     * symptomatic spleen enlargement;\n     * local symptoms or compromise of normal organ function due to tumor mass;\n     * presence of ascites or pleural effusion;\n     * presence of B symptoms (fever, night sweats, or unintentional weight loss of \\>10% over ≤6 months);\n     * serum lactate dehydrogenase or beta-2-microglobulin above upper limit of normal;\n     * cytopenias due to underlying lymphoma (i.e., absolute neutrophil count \\\u003C1.0 × 109\u002FL, hemoglobin \\\u003C10 g\u002FdL, and\u002For platelet count \\\u003C100 × 109\u002FL).\n   * Patients with MZL must have an indication to start therapy as assessed by the investigator.\n8. Performance status ECOG 0, 1, or 2.\n9. Adequate hematologic function (unless due to underlying lymphoma as established by bone marrow involvement or splenomegaly):\n\n   * hemoglobin ≥9 g\u002FdL,\n   * absolute neutrophil count ≥1.0 x 109\u002FL,\n   * platelet count ≥75 x 109\u002FL.\n10. Glomerular filtration rate (GFR) ≥40 mL\u002Fmin\u002F1.73m2 using the Mayo Quadratic Formula.\n11. The effects of mosunetuzumab on the developing human fetus are unknown. For this reason and because lenalidomide used in this trial is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) and refrain from donating eggs or sperm throughout the treatment and for 3 months after the last dose of trial therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n12. Agreement to enroll in and comply with all local requirements of the REVLIMID® (lenalidomide) Risk Evaluation and Mitigation Strategy (REMS®) program for the purpose of lenalidomide acquisition.\n\nExclusion Criteria:\n\n1. Grade 3b follicular lymphoma or transformed lymphoma.\n2. Prior treatment with any anti-CD20 antibody or lenalidomide for lymphoma.\n3. Prior stem cell transplantation (autologous or allogeneic) or prior solid organ transplantation.\n4. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.\n5. Known NYHA class 3\u002F4 congestive heart failure, LVEF \\\u003C40%, myocardial infarction within 6 months prior to enrollment, unstable angina, or unstable arrhythmia.\n6. Chronic obstructive pulmonary disease (COPD) requiring oral corticosteroids or chronic oxygen.\n7. History of autoimmune disease, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, idiopathic pulmonary fibrosis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, granulomatosis with polyangiitis, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, with the exception of: hypothyroidism (on stable dose of thyroid replacement therapy), asthma managed with inhaled medications only; type 1 diabetes mellitus on stable insulin regimen, Sjögren syndrome, immune thrombocytopenia or autoimmune hemolytic anemia that does not require systemic therapy; dermatologic condition (including eczema, psoriasis, lichen simplex chronicus, or vitiligo) with skin manifestations with rash covering \\\u003C10% of body surface area and not requiring treatment other than low-potency topical corticosteroids for \\>12 months prior to registration.\n8. Use of any systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment using \\\u003C10 mg\u002Fday prednisone or equivalent within 2 weeks prior to first treatment; a brief course of palliative corticosteroids at higher doses (prednisone up to 100 mg daily, for up to 7 days) is allowed, but must be completed at least 7 days before the first dose of mosunetuzumab.\n9. Any of the following conditions:\n\n   * active bacterial infection requiring antibiotics\n   * known or suspected chronic active Epstein Barr virus (CAEBV) infection\n   * history of hemophagocytic lymphohistiocytosis (HLH)\n   * confirmed progressive multifocal leukoencephalopathy (PML)\n   * known active EBV or CMV viremia\n   * positive test for hepatitis B surface antigen (HBSAg). Patients with a positive total\u002FIgG hepatitis B core antibody (HBcAb) may participate if hepatitis B virus (HBV) DNA is undetectable at screening, if they agree to take entecavir or tenofovir, and undergo periodic DNA testing\n   * positive hepatitis C virus (HCV) antibody, unless a negative polymerase chain reaction (PCR) for HCV is documented\n   * positive test for HIV.\n10. Administration of a live, attenuated vaccine within 4 weeks before first mosunetuzumab dose or anticipation that such a live, attenuated vaccine will be required during the study.\n11. Current or past history of CNS disease, including stroke, epilepsy, or CNS vasculitis, or an advanced neurodegenerative disease; with the exception of: stroke \\>2 years before registration without any residual neurologic deficits and no subsequent transient ischemic attacks; history of epilepsy with no seizures for \\>2 years and not using any antiepileptic therapy; well-controlled Parkinson's disease (with no need for a significant medication adjustment for \\> 6 months).\n12. History of other malignancy that could affect compliance with the protocol or interpretation of results; patients with a curatively treated skin cancer, in situ cervical cancer, or another malignancy treated curatively with a documented remission \\>2 years before registration are eligible.\n13. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before the first dose of mosunetuzumab.\n14. Clinically significant liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.\n15. Any major surgery within 4 weeks before the first dose of mosunetuzumab, other than lymph node biopsy for diagnosis.\n16. Evidence of other significant or uncontrolled medical or psychiatric conditions that could affect compliance with the protocol.\n17. Any of the following abnormal laboratory values within 14 days prior to first dose of mosunetuzumab:\n\n    * AST or ALT \\>3x ULN\n    * total bilirubin \\>2 x ULN (unless due to Gilbert syndrome with indirect hyperbilirubinemia only)\n    * INR\\>1.5 x ULN without anticoagulation\n    * PTT or APTT \\>1.5x ULN in the absence of lupus anticoagulant.\n18. Any radiation therapy within 2 weeks prior to first dose of mosunetuzumab.\n19. Pregnancy, breast-feeding, or prisoner status. Women of childbearing potential must have a negative pregnancy test within 2 weeks before first dose of mosunetuzumab, and must undergo repeat pregnancy testing during each cycle of lenalidomide therapy (see Inclusion Criterion 11).",{"count":425,"type":23},52,[64],"BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients who achieve PR at IRA will receive mosunetuzumab with lenalidomide augmentation during C5-8. Primary response assessment (PRA) will occur after C8. Patients who remain in PR at PRA will continue for additional 4 cycles (extended augmentation).",[429,430,431],"Follicular Lymphoma","Marginal Zone Lymphoma","B-cell Lymphoma","2025-12-27",{"date":411,"type":43},{"date":435,"type":43},"2022-07-14",{"date":213,"type":23},{"name":49,"class":50},3,{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":143,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":24,"phases":449,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":51},"100590289","systematic-psychophysical-100590289","NCT06965478","Systematic Psychophysical","Systematic Psychophysical Investigation of Visual Learning","Inclusion Criteria:\n\n* Ages 18 - 60,\n* Normal or corrected-to-normal vision\n\nExclusion Criteria:\n\n* Eye disorders (cataracts, age related macular degeneration, diabetic retinopathy, glaucoma)\n* Drug use (psychoactive drugs, neuroleptic medications, prescription medications that might affect cognitive and motor performance)\n* Sleep disorders (sleep apnea, insomnia)\n* Magnetically or mechanically activated implants (such as cardiac pacemakers)\n* clips on blood vessels in the brain\n* intrauterine devices\n* dentures\n* pregnancy","60 Years",{"count":448,"type":23},400,[26],"The purpose of this study is to investigate how our performance changes after our perceptual system is trained in a certain way (\"perceptual learning\"). In addition, investigators are interested in identifying and characterizing relationships between such changes and neuroimaging signals recorded from the human brain.",[452],"Perceptual Learning",[155],"2025-11-17",{"date":456,"type":43},"2025-11-19",{"date":458,"type":43},"2025-07-22",{"date":460,"type":23},"2029-01",{"name":49,"class":50},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":470,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":51},"100590990","phase-2-preventing-dato-dxd-associated-stomatitis-with-dexamethasone-mouthwash-tropion-dm-100590990","NCT06974604","Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM","Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)","Inclusion Criteria:\n\n* Has advanced and\u002For metastatic cancer that meets one of the following criteria:\n\n  1. Pathologically documented unresectable advanced non-squamous NSCLC not amenable to curative therapy that has progressed on at least one prior therapy.\n  2. Pathologically documented triple negative breast cancer (estrogen receptor negative and progesterone receptor negative and HER2 negative) who have progressed on at least 1 prior line of therapy or in the opinion of the treating physician, not be a candidate for standard first-line metastatic breast cancer therapy\n  3. Pathologically documented hormone receptor positive breast cancer (estrogen receptor and\u002For progesterone receptor positive, HER2 negative) which has progressed on hormonal based therapy including CDK4\u002F6 inhibitor and 1 prior line of chemotherapy and\u002For antibody drug conjugate therapy.\n* Aged ≥18 years.\n* Has an Eastern Cooperative Oncology Group performance status 0-2.\n* Has a left ventricular ejection fraction (LVEF) 50% by either an echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days before enrollment.\n* Measurable disease based on Response Evaluation Criteria in Solids Tumors (RECIST) version 1.1.\n* Has adequate organ function that would make them an appropriate candidate for Datopotamab deruxtecan therapy as treatment of advanced metastatic cancer as assessed by the treating physician, which shall include results of complete blood count with differential, and comprehensive metabolic panel within 14 days before Cycle 1, Day 1, defined as:\n\n  1. Platelet count ≥100,000\u002Fmm3\n  2. Hemoglobin ≥9.0 g\u002FdL\n  3. Absolute neutrophil count ≥1000\u002Fmm3\n  4. Creatinine clearance ≥30 mL\u002Fmin as calculated using the Cockcroft-Gault equation.\n  5. Aspartate aminotransferase ≤3 ×ULN (if liver metastases are present, ≤5 × ULN)\n  6. Alanine aminotransferase ≤3 × ULN (if liver metastases are present, ≤5 × ULN)\n  7. Total bilirubin ≤1.5 × ULN if no liver metastases or liver \\\u003C 3 if liver metastases are present.\n* Has an adequate treatment washout period prior to Cycle 1, Day 1, defined as appropriately recovering from:\n\n  1. Major surgery: ≥2 weeks (or 2 weeks for low-invasive cases \\[eg, colostomy\\]).\n  2. Radiation therapy (curative) and palliative radiation therapy to lung fields: ≥4 weeks; ≥2 weeks (palliative radiation therapy to other areas \\[ie, limited field and 10 or fewer days or fractions\\] including whole brain radiotherapy).\n  3. Hormonal therapy: ≥2 weeks\n  4. Chemotherapy (including immunotherapy \\[non-antibody based therapy\\]), and retinoid therapy: ≥2 weeks or 5 times terminal elimination half-life (T½) of the chemotherapeutic agent (whichever is longer); ≥6 weeks for nitrosoureas or mitomycin C, ≥1 week for tyrosine kinase inhibitors (TKIs)\n  5. Antibody-based anti-cancer therapy: ≥4 weeks\n  6. Chloroquine\u002Fhydroxychloroquine: \\>14 days\n* If of reproductive\u002Fchild-bearing potential, agrees to use a highly effective form of contraception or avoid intercourse throughout treatment and upon completion of the study for at least 7 months for females and 4 months for males after the last dose of study drug. Highly effective methods of birth control include: combined (estrogen and progesterone containing) hormonal contraception by oral or intravaginal route or dermal patches; progesterone-only hormonal contraception associated with inhibition of ovulation given by oral route or by injections or implants; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner (with confirmation of surgical success); and complete heterosexual abstinence.\n* Starting at the time of randomization\u002Ffirst dose of study intervention male subjects\u002Fparticipants must not freeze or donate sperm at any time during this study and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to randomization\u002Ffirst dose of study intervention.\n* Starting at the time of randomization\u002Ffirst dose of study intervention female subjects\u002Fparticipants must not breastfeed or donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to randomization\u002Ffirst dose of study intervention.\n* Is able to provide written informed consent and is willing and able to comply with the protocol. Subject must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible toxicities) and must sign and date the Institutional Review Board (IRB)\u002FIndependent ethics committee (IEC) approved informed consent form (ICF) (including Health Insurance Portability and Accountability Act authorization \\[HIPAA\\], if applicable) before performance of any study- specific procedures or examinations.\n* Willingness to self-report level of oral pain using Visual Analog Scale (VAS) and the Normalcy Diet Scale (NDS) throughout each stomatitis event. (40, 41) At baseline, patient's self-reported oral pain level, using VAS, must be 0 (See Appendix B) and the normalcy diet scale score should ≥ 60 (See Appendix C).\n* Willingness to record oral symptoms in Oral Diary (See Appendix D).\n* Has a life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Active second malignancy which would alter interpretation of study results.\n* Has a history of non-infectious ILD\u002Fpneumonitis including radiation pneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Has clinically significant corneal disease\n* Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd.\n* Has a history of severe hypersensitivity reactions to other monoclonal antibodies.\n* Has ongoing radiation-related toxicities\n* Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.\n* Has active human immunodeficiency virus (HIV) infection that is not well controlled.\n* Has an active or uncontrolled hepatitis B and\u002For hepatitis C infection\n* Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment.\n* Clinically severe pulmonary compromise resulting from autoimmune, connective tissue or inflammatory disorders with pulmonary involvement.\n* Has uncontrolled or significant cardiac disease (including MI or unstable angina within the past 6 months, NYHA Class II-IV heart failure, uncontrolled hypertension, uncontrolled or significant arrhythmia).\n\nPatients with the following may be enrolled based on the investigator's\u002Ftreating physician's assessment (documentation must be submitted to BrUOG). -Mean resting corrected QTcF interval \\> 470 ms.\n\n* History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.\n* Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.",{"count":197,"type":23},[64],"TROPION-DM\u002FBrUOG-431 is a prospective, , phase 2 trial with two non-comparative cohorts analyzed jointly for primary endpoint in adult patients with either (Cohort 1:) advanced\u002Fmetastatic hormone-receptor positive (\\[HR+\\], estrogen receptor and\u002For progesterone receptor positive) breast cancer (BC), or advanced\u002Fmetastatic triple negative breast cancer (TNBC) or (Cohort 2:) advanced\u002Fmetastatic non-squamous non-small cell lung cancer (NSCLC).\n\nAll patients will be treated with Datopotumab deruxtecan (Dato-DXd) at 6 mg\u002Fkg IV every 3 weeks until disease progression or unacceptable toxicity. Due to the risk of stomatitis, the investigational component of this trial will be to incorporate alcohol-free dexamethasone mouthwash, 10 mL 0.5 mg\u002F5mL oral solution, days 1-5, swish and spit four times daily for the first 3 cycles.",[473,474],"Breast Neoplasms","Lung Neoplasms",[476,477,478],"Advanced\u002Fmetastatic hormone-receptor positive [HR+], estrogen receptor and\u002For progesterone receptor positive","Advanced\u002Fmetastatic triple negative breast cancer","Advanced\u002Fmetastatic non-squamous, non-small cell lung cancer","2025-10-23",{"date":481,"type":43},"2025-10-24",{"date":483,"type":43},"2025-10-22",{"date":485,"type":23},"2029-05-31",{"name":49,"class":50},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":495,"maxAge":446,"enrollmentInfo":496,"targetDuration":4,"studyType":24,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":438},"100438867","skills-to-enhance-positivity-in-suicidal-youth-100438867","NCT04994873","Skills to Enhance Positivity in Suicidal Youth","Skills to Enhance Positivity in Adolescents at Risk for Suicide","STEP","Inclusion Criteria: Patients\n\n* Ages 12- 60 years\n* hospitalized on an inpatient psychiatric unit due to suicide risk\n* past month suicide attempts or suicidal ideation\n* proficient in English (parent either English or Spanish\n* access to a smart phone.\n\nInclusion Criteria: Stakeholders\n\nAges 22 - 60 years\n\n* work with adolescents hospitalized on an inpatient psychiatric unit due to suicide risk\n* proficient in English or Spanish\n\nExclusion Criteria:\n\n* active psychotic disorder\n* significant cognitive impairment or deficits\n* ward of the State\n* discharge to residential facility.","12 Years",{"count":497,"type":23},216,[26],"This is a Hybrid Type I Effectiveness-Implementation design. Specifically, this study proposes to test the effectiveness of STEP in reducing suicidal events and ideation in 216 adolescents, admitted to inpatient psychiatric care due to suicide risk. Participants will be randomized to either STEP or ETAU. STEP involves 4 in-person sessions (3 individual, 1 family) focused on psychoeducation regarding positive and negative affect, mindfulness meditation, gratitude, and savoring. Mood monitoring prompts and skill reminders will be sent daily for the first month post-discharge and three times a week for the following two months. The ETAU condition will receive reminders to log into a safety resource app, matched in frequency to the STEP group. Effectiveness aspects of the design include using clinical staff as interventionists and having very few exclusion criteria.",[501],"Suicide, Attempted","2025-10-11",{"date":504,"type":43},"2025-10-15",{"date":506,"type":43},"2021-10-04",{"date":508,"type":23},"2026-09-01",{"name":49,"class":50},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":518,"phases":4,"briefSummary":519,"conditions":520,"keywords":544,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":51},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",{"count":517,"type":23},800,"OBSERVATIONAL","This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543],"Chronic Pain","Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[545,546,547,548,549,550,551,552,553],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":556,"type":43},"2025-09-19",{"date":558,"type":43},"2023-06-20",{"date":560,"type":23},"2026-05-30",{"name":49,"class":50},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":569,"minAge":59,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":578,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":51},"100520397","making-art-work-among-brazilian-youth-100520397","NCT06056037","Making ART Work Among Brazilian Youth","Making Universal, Free-of-charge Antiretroviral Therapy Work for Sexual and Gender Minority Youth in Brazil","Inclusion Criteria:\n\n* between 18 and 24 years of age\n* assigned male sex at birth\n* identify as a gay or bisexual man, or a transgender woman or another gender identity along the feminine spectrum\n* self-report living with HIV, and verified by medical chart review,\n* self-report currently taking or prescribed ART for \\> 3 months\n* self-report missing 2 or more doses of ART medications in any given week in the past month OR not virally suppressed (i.e., \\>40 copies\u002FmL in past 3 months; via national outpatient data \\[SISCEL\\] or plasma viral load testing)\n* owns a cell phone or willing to use one as part of the study\n\nExclusion Criteria:\n\n* unable to give informed consent due to cognitive limitation, severe mental\u002Fphysical illness or intoxication\n* unable to read and\u002For write to an extent that would limit their ability to comprehend the informed consent\n* lived in the greater Rio de Janeiro area for \\\u003C 3 months or planning to move outside the area within the next year","MALE","24 Years",{"count":572,"type":23},72,[26],"This study seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among sexual and gender minority (SGM) young people living with HIV (ages 18-24) in Rio de Janeiro, Brazil. The intervention aims to improve social support, self-efficacy for taking ART, and teach skills for problem-solving barriers to promote better adherence.",[576,577],"Hiv","Adherence, Medication",[579,580,581,582,583],"Brazil","sexual and gender minority","adolescents","HIV","Medication adherence","2025-09-15",{"date":556,"type":43},{"date":587,"type":43},"2023-10-01",{"date":589,"type":23},"2026-04-30",{"name":49,"class":50},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":24,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":51},"100515217","phase-1-intranasal-insulin-for-treatment-of-alcohol-use-disorder-100515217","NCT05988632","Intranasal Insulin for Treatment of Alcohol Use Disorder","ITA","Inclusion Criteria:\n\n* ≥21 years\n\n  * meet any DSM-5 criteria score for AUD\n  * Individuals who, in the last month, have consumed at least the same amount of alcohol that will be administered in the laboratory procedure (i.e. to reach BrAC levels of 0.08g\u002Fdl, \\~two drinks in one occasion)\n  * BrAC=0.00g\u002FdL at each visit\n  * good health as confirmed by medical history, physical examination and lab tests\n  * willing to adhere to the study procedures\n  * understand informed consent and questionnaires in English at an 8th grade level\n  * willing to have glucose monitored by finger stick during the laboratory procedures\n\nExclusion Criteria:\n\n* • female identifying who are breastfeeding or pregnant (assessed by a urine screen)\n\n  * individuals with diabetes\n  * history of suicide attempts in the last three years\n  * current diagnosis of other substance use disorder (other than nicotine or cannabis)\n  * use of drugs (e.g. stimulants\u002Fopioids) at each alcohol administration session (by urine tox screen)\n  * cannabis intoxication (by clinical assessments)\n  * use of medications that may interact with insulin and alcohol (by Micromedex database)\n  * hypersensitivity to insulin\n  * any nasal disease\u002Fcongestion that may interfere with intranasal drug absorption;\n  * baseline hypoglycemia (blood glucose ≤65mg\u002FdL) or hyperglycemia (blood glucose \\>200mg\u002FdL) (by finger stick)",{"count":599,"type":23},40,[63,64],"This is a randomized controlled trial (RCT), within-subject, crossover, double-blind, placebo-controlled in non-treatment-seeking individuals with Alcohol Use Disorder (AUD) (N=40, 50% female) randomized to IN insulin or placebo. In a bar laboratory setting, randomized participants will receive a single dose of IN insulin (80IU) or an IN matched placebo (0.9% Saline). Participants will undergo a cue-reactivity paradigm followed by an alcohol challenge that includes an alcohol drink designed to raise the breath alcohol content (BrAC) to 0.08g\u002FdL.",[603],"Alcohol Use Disorder","2025-08-28",{"date":606,"type":43},"2025-09-05",{"date":608,"type":43},"2025-02-25",{"date":47,"type":23},{"name":49,"class":50},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":619,"briefSummary":620,"conditions":621,"keywords":624,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":51},"100549606","cognitive-control--the-functional-organization-of-the-frontal-cortex-100549606","NCT06436209","Cognitive Control & the Functional Organization of the Frontal Cortex","Inclusion Criteria:\n\n* Normal or corrected to normal vision.\n\nExclusion Criteria:\n\n* Left handedness\n* Presence or history of neurological or psychiatric disorders\n* Usage of brain related medications\n* Previous head injury and time spent unconscious\n* Any implanted medial fragment or device in the body of the participant.\n* Tattoos above the neck\n* Injury to the eye or other body part involving a metallic object or fragment.\n* Welding, grinding, or cutting of metal in lifetime of participant without usage of safety protection glasses.\n* injury to the participant by a metallic object or foreign body (e.g., BB, bullet, shrapnel, etc.)\n* Pregnancy or possibility of pregnancy\n* Implants or devices including:\n\nElectronic implant or device, Magnetically-activated implant or device, Cardiac pacemaker, Implanted cardioverter defibrillator (ICD), Aneurysm clip(s), Neurostimulation system, Spinal cord stimulator, Internal electrodes or wires, Bone growth\u002Fbone fusion stimulator, Cochlear, otologic, or other ear implant, Insulin or infusion pump, Implanted drug infusion device, Any type of prosthesis (eye, penile, etc.), Heart valve prosthesis, Eyelid spring or wire, Artificial or prosthetic limb, Metallic stent, filter, or coil, Shunt (spinal or intraventricular), Vascular access port and\u002For catheter, Radiation seeds or implants, Swan-Ganz or triple lumen catheter, Medication patch (Nicotine,Nitroglycerine), Any metallic fragment or foreign body, Wire mesh implant, Tissue expander (e.g., breast), Surgical staples, clips, or metallic sutures Joint replacement (hip, knee, etc.) Bone\u002Fjoint pin, screw, nail, wire, plate, etc. IUD or diaphragm, Dentures or partial plates, Tattoo or permanent makeup above the neck, Body piercing jewelry that can not be removed, Breathing disorder, Motion disorder or tremors, Claustrophobia, Hearing aid","35 Years",{"count":197,"type":23},[26],"The goal of this basic experimental clinical trial is to understand the effect of multitasking practice on the structure of neural representations of tasks in the human lateral prefrontal cortex and control brain regions. The main question it aims to answer is: What changes in neural representational structure predict improvements in multitasking behavior due to multitasking practice? Healthy human participants will learn two independent tasks, each mapping a set of stimuli to motor responses based on different rules. Participants will be randomized to one of two interventions. Participants assigned to the multitask practice intervention (MPI) will practice multitasking the two tasks over multiple days. Those assigned to the single-task practice intervention (SPI) will instead practice each task separately while controlling for the total number of practice opportunities associated with each task across the interventions. Both before and after the practice, the ability of all participants to perform both tasks simultaneously will be behaviorally measured using a well-established psychological refractory period (PRP) paradigm, and their neural representations will be measured using functional MRI while they perform the two tasks. Researchers will then compare improvements in multitasking behavior across the two groups, as well as changes in neural representational geometry of the tasks in the lateral prefrontal cortex and control brain regions, and test whether multitasking training is associated with specific changes in neural representations in the lateral prefrontal cortex.",[622,152,623],"Multitasking Behavior and Neural Representations Associated With Multitasking Ability","Executive Function",[625],"psychological refractory period (PRP), behavioral training, neural representational geometry, lateral prefrontal cortex, separability and generalizability","2025-08-12",{"date":628,"type":43},"2025-08-15",{"date":630,"type":43},"2024-03-27",{"date":632,"type":23},"2026-07-31",{"name":49,"class":50},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":17,"sex":169,"minAge":59,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":24,"phases":643,"briefSummary":644,"conditions":645,"keywords":649,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":51},"100591351","promoting-physical-activity-and-healthy-eating-in-latinas-100591351","NCT06979297","Promoting Physical Activity and Healthy Eating in Latinas","Promoting Physical Activity and Healthy Eating in Latinas Via Interactive Web-Based Technology","Inclusion Criteria:\n\nAges 18 years and over; Self-identify as Hispanic or Latino (or of a group defined as Hispanic\u002FLatino by the Census Bureau); Report insufficient PA levels (according to the national PA guidelines); Consume less than 1.5 cups of fruit\u002Fday and 2.5 cups of vegetables\u002Fday, and\u002For consume SSB ≥2 times\u002Fweek; Have regular access to an Internet-connected device through phone, home, work, or their community (e.g., public library, community center, neighbor's house); Are not pregnant or planning to become pregnant during the course of the study.\n\nExclusion Criteria:\n\nAny orthopedic condition that would limit their mobility; History of heart disease, stroke or any other health condition that would make PA or dietary change unsafe.",{"count":642,"type":23},70,[26],"The goal of this clinical trial is to learn if an Internet-based behavioral intervention can increase physical activity and improve diet quality among Latina adults. The main question aims to answer is whether participants in the Internet-based behavioral intervention group increase their physical activity levels, increase their consumption of fruits and vegetables, and decrease their consumption of sugar-sweetened beverages over 12 weeks. Researchers will compare the Internet-based physical activity and healthy eating intervention to a wait-list control group (participants who do not receive any intervention until after completing the study) to see if the Internet-based behavioral intervention works to improve physical activity and diet quality. Participants who receive the Internet-based behavioral intervention receive access to the online intervention for 12 weeks, and complete assessments at baseline and week-12. Participants in the wait-list control complete the same assessments at baseline and week 12, then receive access to the online intervention for 12 weeks.",[646,647,648],"Physical Inactivty","Physical Activity","Diet Quality",[650,651,652,653,654],"healthy eating","dietary intervention","lifestyle intervention","physical activity","physical inactivity","2025-06-02",{"date":657,"type":43},"2025-06-03",{"date":659,"type":43},"2025-05-28",{"date":661,"type":23},"2027-07-31",{"name":49,"class":50},""]